Resectable Pancreatic Ductal Adenocarcinoma
Conditions
Keywords
Pancreatic, Cancer, Resectable
Brief summary
The primary objective of this study is to evaluate the rate of pathologic complete response to neoadjuvant FOLFIRINOX in patients with resectable pancreatic cancer using a tissue collection component.
Interventions
DRUGFOLFIRINOX
FOLFIRINOX consists of the following combination of drugs: 1. Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle 2. Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle 3. Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle. 5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle.
Sponsors
Indiana University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. ≥ 18 years old at the time of informed consent 2. Able to provide written informed consent and HIPAA authorization 3. ECOG performance status of 0 or 1 4. Patient must be eligible for abdominal surgery 5. Histologically confirmed adenocarcinoma of the pancreas that has been documented to be resectable by standardized radiographic criteria by a pancreatic surgeon 6. Patients must to have tumor tissue collected prior to enrolling on this trial. Up to 10 patients will be accepted with no pre-treatment research tissue collection or tissue collection from an outside institution. a.If the tissue is from an outside institution, it must be reviewed at Indiana University Health Pathology Department if a biopsy was performed outside of this institution. 7. Women of childbearing potential definition (WOCBP) must have a negative serum or urine pregnancy test performed within 14 days prior to initiation of FOLFIRINOX. Any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) is classified as WOCBP if she meets the following criteria: 1. Has not undergone a hysterectomy or bilateral oophorectomy; or 2. Has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). 8. WOCBP and men must agree to use adequate contraception prior, to study entry, for the duration of study participation, and 8 weeks after the end of treatment. 9. Patients must have adequate organ function as defined by the following laboratory values at study entry: 1. Hemoglobin ≥ 9 g/dL (transfusions are acceptable) 2. ANC ≥ 1.5 x 109/L 3. Platelets ≥ 100 x 109/L 4. Creatinine ≤ 1.5 x ULN, or creatinine clearance ≥ 50 mL/min (estimated by Cockcroft-Gault or measured) 5. Total bilirubin ≤ 1.5 x ULN 6. AST/ALT ≤ 3 x ULN
Exclusion criteria
1. Prior therapy for pancreatic adenocarcinoma 2. Other malignancies within the past 3 years except for the following: adequately treated cervical or vulvar carcinoma in situ, treated basal cell or squamous carcinoma of the skin, superficial bladder tumors (Ta, Tis & T1), ductal carcinoma in situ (DCIS) of the breast and low grade prostate cancer. Any cancer curatively treated \>3 years prior to entry with no clinical evidence of recurrence is permitted. 3. Hypersensitivity to 5FU, oxaliplatin (or other platinum agents), irinotecan (or to their excipients). 4. Participation in any investigational drug study within 4 weeks preceding the start of study treatment. Patients are not permitted to participate in another investigational drug study while being treated on this protocol. 5. Inability to receive a port or PICC line. 6. History of or suspected Gilbert's Disease (testing not required if presence is not suspected). 7. Baseline peripheral neuropathy/paresthesia grade ≥ 1. 8. Active hepatitis B, unless patient has been on antiviral agents for at least 2 months (baseline testing not required). 9. Active clinically serious infections (\> grade 2). 10. Major surgery or significant traumatic injury within 8 weeks of first study drug. A core pancreatic or liver biopsy does not preclude the patient from the study. 11. Unable or unwilling to discontinue use of ketoconazole or St John's wort. Use of phenytoin, carbamazepine, phenobarbital, rifampin and rifabutin is discouraged, but not contraindicated. If patients require phenytoin, carbamazepine or phenobarbital monitoring of drug levels is suggested during the study. 12. Pregnant or lactating women. 13. Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients With Pathologic Complete Response | Up to 4 months | Pathologic complete response was evaluated using MRI or CT and Evan's criteria for pathologic response following neoadjuvant therapy: I: \<10% to no tumor cells destroyed IIa: 10-50% of tumor cells destroyed IIb: 50-90% of tumor cells destroyed III: \>90% of tumor cells destroyed IIIM: sizable pools of cellular mucin IV: No viable tumor cells (complete pathologic response) IVM: Acellular pools of mucin |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With Treatment-Related Adverse Events Grade 3 or Above | Every 15 days for approximately 6 months | Number of unique patients who had a treatment-related (possible, probable, or definite) adverse event with grade 3 or greater using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. |
| Percentage of Patients Who Successfully Underwent Surgery After Neoadjuvant FOLFIRINOX | Up to 4 months | The percentage of patients who successfully underwent surgery after neoadjuvant FOLFIRINOX and its 95% confidence interval will be provided. |
| Rate of R0 Resection | Up to 4 months | The percentage of patients with a final margin status of R0 after resection of their primary tumor and its 95% confidence interval will be provided. R0 resection indicates a microscopically margin-negative resection, in which no cancer cells seen microscopically at the primary tumor site. |
| Disease Free Survival | Up to 3 years | Disease free survival is defined as the time from on study date to evidence of tumor recurrence or death from any cause. Patients who remained alive and disease free were censored at their date of last disease evaluation. |
| Overall Survival | Up to 4 years | Overall survival was defined as the time from on study date to death due to any cause. Patients who remained alive were censored at their last known alive date. The Kaplan-Meier method was used to determine the median and 95% confidence interval. |
| Objective Response Rate (Percentage of Patients With Complete Response or Partial Response) | Up to 4 months | Measured by RECIST v1.1 Complete response: Disappearance of all target lesions Partial response: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter The percentage of patients with objective response and its 95% confidence interval will be provided. |
| Disease Control Rate (Percentage of Patients With Complete Response, Partial Response, or Stable Disease) | Up to 4 months | Measured by RECIST v1.1 Complete response: Disappearance of all target lesions Partial response: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter Stable disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started The percentage of patients with objective response and its 95% confidence interval will be provided. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| FOLFIRINOX FOLFIRINOX consists of the following combination of drugs:
1. Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle
2. Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle
3. Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.
5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle. | 48 |
| Total | 48 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 5 |
| Overall Study | Death | 2 |
| Overall Study | Disease Progression | 5 |
| Overall Study | Physician Decision | 2 |
| Overall Study | Withdrawal by Subject | 2 |
Baseline characteristics
| Characteristic | FOLFIRINOX |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 26 Participants |
| Age, Categorical Between 18 and 65 years | 22 Participants |
| Age, Continuous | 62.9 years STANDARD_DEVIATION 9.19 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 47 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 43 Participants |
| Sex: Female, Male Female | 18 Participants |
| Sex: Female, Male Male | 30 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 35 / 48 |
| other Total, other adverse events | 42 / 48 |
| serious Total, serious adverse events | 15 / 48 |
Outcome results
Primary
Percentage of Patients With Pathologic Complete Response
Pathologic complete response was evaluated using MRI or CT and Evan's criteria for pathologic response following neoadjuvant therapy: I: \<10% to no tumor cells destroyed IIa: 10-50% of tumor cells destroyed IIb: 50-90% of tumor cells destroyed III: \>90% of tumor cells destroyed IIIM: sizable pools of cellular mucin IV: No viable tumor cells (complete pathologic response) IVM: Acellular pools of mucin
Time frame: Up to 4 months
Population: All patients who received at least two doses of FOLFIRINOX (unless treatment-related toxicity precluded additional doses) and had at least one post-baseline assessment or died before any evaluation.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FOLFIRINOX | Percentage of Patients With Pathologic Complete Response | 0 percentage of participants |
Secondary
Disease Control Rate (Percentage of Patients With Complete Response, Partial Response, or Stable Disease)
Measured by RECIST v1.1 Complete response: Disappearance of all target lesions Partial response: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter Stable disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started The percentage of patients with objective response and its 95% confidence interval will be provided.
Time frame: Up to 4 months
Population: Patients who received four treatments of FOLFIRINOX and had at least one post-baseline assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FOLFIRINOX | Disease Control Rate (Percentage of Patients With Complete Response, Partial Response, or Stable Disease) | 88.2 percentage of participants |
Secondary
Disease Free Survival
Disease free survival is defined as the time from on study date to evidence of tumor recurrence or death from any cause. Patients who remained alive and disease free were censored at their date of last disease evaluation.
Time frame: Up to 3 years
Population: All patients who received at least two doses of FOLFIRINOX (unless treatment-related toxicity precluded additional doses) and had at least one post-baseline assessment or died before any evaluation.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| FOLFIRINOX | Disease Free Survival | 8.6 months |
Secondary
Number of Patients With Treatment-Related Adverse Events Grade 3 or Above
Number of unique patients who had a treatment-related (possible, probable, or definite) adverse event with grade 3 or greater using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Time frame: Every 15 days for approximately 6 months
Population: All patients who received at least one dose of FOLFIRINOX.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| FOLFIRINOX | Number of Patients With Treatment-Related Adverse Events Grade 3 or Above | 14 Participants |
Secondary
Objective Response Rate (Percentage of Patients With Complete Response or Partial Response)
Measured by RECIST v1.1 Complete response: Disappearance of all target lesions Partial response: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter The percentage of patients with objective response and its 95% confidence interval will be provided.
Time frame: Up to 4 months
Population: Patients who received four treatments of FOLFIRINOX and had at least one post-baseline assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FOLFIRINOX | Objective Response Rate (Percentage of Patients With Complete Response or Partial Response) | 17.7 percentage of participants |
Secondary
Overall Survival
Overall survival was defined as the time from on study date to death due to any cause. Patients who remained alive were censored at their last known alive date. The Kaplan-Meier method was used to determine the median and 95% confidence interval.
Time frame: Up to 4 years
Population: All patients who received at least two doses of FOLFIRINOX (unless treatment-related toxicity precluded additional doses) and had at least one post-baseline assessment or died before any evaluation.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| FOLFIRINOX | Overall Survival | 15.7 months |
Secondary
Percentage of Patients Who Successfully Underwent Surgery After Neoadjuvant FOLFIRINOX
The percentage of patients who successfully underwent surgery after neoadjuvant FOLFIRINOX and its 95% confidence interval will be provided.
Time frame: Up to 4 months
Population: All patients who received at least two doses of FOLFIRINOX (unless treatment-related toxicity precluded additional doses) and had at least one post-baseline assessment or died before any evaluation.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FOLFIRINOX | Percentage of Patients Who Successfully Underwent Surgery After Neoadjuvant FOLFIRINOX | 76.7 percentage of participants |
Secondary
Rate of R0 Resection
The percentage of patients with a final margin status of R0 after resection of their primary tumor and its 95% confidence interval will be provided. R0 resection indicates a microscopically margin-negative resection, in which no cancer cells seen microscopically at the primary tumor site.
Time frame: Up to 4 months
Population: All patients who completed surgery.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FOLFIRINOX | Rate of R0 Resection | 75.8 percentage of participants |